Inclusion Criteria:  Patients suffering from neuro-ischemic diabetic foot ulcer grade IC or IIC according to the University of Texas Wound Classification; If the patient has two or more lesions, which may fall within the inclusion criteria, the most serious lesion (index lesion) will be selected and followed for the entire duration of the study. Patients who, following hospital discharge or after the first outpatient assessments, are followed by Home Care and are always monitored at the same referral center; Patients with type I or II diabetes, with blood glucose ≤ 10%; Patients willing to constantly wear the offload braces prescribed by the reference center; Patients with ulcer localized on the finger, lateral, plantar, or dorsal part of the foot with an extension greater than 1 sqcm; Patients with confirmed neuropathy with Monofilament (Semmes-Weinstein 5.07 / 10g); Patients with ABPI between 0.7 - 0.9, ankle PA> 70mmHg, TcPO2 between 36 - 50 mmHg; Patients with lesions lasting between 1 and 24 months; Patients who understand the purpose of the Clinical Study and provide their informed consent in writing.  Exclusion Criteria:  Patients who have participated in a clinical study with a drug or medical device for less than a month; Patients who are unable to understand the aims and objectives of the study; Patients who are bedridden or unable to walk or Patients with neoplasms; Patients with pressure ulcers; Patients who have infectious signs according to IDSA criteria; Patients who underwent revascularization in the previous two months; Patients who have presented an acute ischemic event within the previous 3 months; Patients with heel injuries; Patients with nephropathy undergoing dialysis; Patients with osteomyelitis; Patients with Charcot's neuro-arthropathy: Patient on high dose corticosteroid therapy (≥ 40 mg/day); Patients with a history of self-harm who can voluntarily alter the course of healing; Patients with psychiatric disorders; Women who are pregnant or breastfeeding; Patients with pathologies or under treatment with drugs that induce photosensitization of the skin; Patients with a life expectancy of less than one year.